Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The addition of anthracyclines to adjuvant taxane-based chemotherapy improved survival for certain high-risk patients with ...
T-DXd outperformed physician’s choice of chemotherapy regardless of patients’ disease burden or time to progression on prior therapy.
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows ...
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA ... Vandana Singh Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study Merck reported ...
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...
AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...
CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback